UNDERSTANDING AND ADDRESSING NEUTROPENIA
ABRAXANE PHASE III MBC TRIAL
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation
The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.
Please see Important Safety Information and Prescribing Information, including Boxed WARNING.
Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Bristol Myers Squibb
The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.
Please see Important Safety Information and Prescribing Information, including Boxed WARNING.
Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com
YOU ARE NOW LEAVING www.abraxanepro.com
Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com
FOR HEALTHCARE PROFESSIONALS
The information contained in this section of www.abraxanepro.com is technical in nature and is intended for US healthcare professionals only.
If you are not a US healthcare professional, click “CANCEL” below to return to the patient and caregiver section of the site. Click “OK” if you are a healthcare professional.
OK CANCELFOR HEALTHCARE PROFESSIONALS
The information contained in this section of www.abraxanepro.com is technical in nature and is intended for US healthcare professionals only.
If you are not a US healthcare professional, click “CANCEL” below to return to the patient and caregiver section of the site. Click “OK” if you are a healthcare professional.
OK CANCEL